Abstract
Stroke is a frequent cause of epileptic seizures (ES) in adults. The authors evaluated the long-term efficacy and tolerability of gabapentin (900 to 1,800 mg/day) in 71 patients with a first poststroke late ES during a mean follow-up time of 30 months. ES recurred in 18.3% of the patients and side effects were noted in 27 cases (38%), but only two (2.8%) required discontinuation or early withdrawal. Gabapentin monotherapy was useful and safe for late poststroke ES.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acetates / adverse effects
-
Acetates / therapeutic use*
-
Aged
-
Amines*
-
Anticonvulsants / adverse effects
-
Anticonvulsants / therapeutic use*
-
Cyclohexanecarboxylic Acids*
-
Dose-Response Relationship, Drug
-
Female
-
Follow-Up Studies
-
Gabapentin
-
Humans
-
Male
-
Middle Aged
-
Prospective Studies
-
Recurrence
-
Seizures / drug therapy*
-
Seizures / etiology*
-
Stroke / complications*
-
gamma-Aminobutyric Acid*
Substances
-
Acetates
-
Amines
-
Anticonvulsants
-
Cyclohexanecarboxylic Acids
-
gamma-Aminobutyric Acid
-
Gabapentin